Tenecteplase

Drug Profile

Tenecteplase

Alternative Names: Metalyse; RG3625; TNK; TNK-tPA; TNKase

Latest Information Update: 26 Sep 2014

Price : $50

At a glance

  • Originator Genentech
  • Developer Boehringer Ingelheim; Genentech; Roche Canada
  • Class Blood coagulation factors; Plasminogen activator enzymes; Serine endopeptidases; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myocardial infarction
  • Discontinued Catheter thrombosis; Heart arrest

Most Recent Events

  • 13 Mar 2013 Discontinued - Phase-III for Catheter thrombosis in USA (IV)
  • 11 Mar 2013 Efficacy and adverse events data from the Phase-III STREAM trial in Myocardial infarction presented at the 62nd Annual Scientific Session of the American College of Cardiology (ACC-2013)
  • 01 Jan 2013 Launched for Myocardial infarction in Singapore (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top